Merdad Parsey - 13 Jul 2023 Form 3 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Director
Signature
/s/ Dennis Hom, Attorney-in-Fact
Issuer symbol
SGMT
Transactions as of
13 Jul 2023
Net transactions value
$0
Form type
3
Filing time
13 Jul 2023, 21:05:14 UTC
Previous filing
14 Jun 2023
Next filing
20 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SGMT Common Stock 8,677 13 Jul 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGMT Series E Preferred Stock 13 Jul 2023 Common Stock 4,117 Direct F1
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 2,086 $11.13 Direct F2
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 3,349 $23.05 Direct F2
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 144 $23.05 Direct F2
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 23,216 $6.36 Direct F2
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 23,839 $6.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series E Preferred Stock is convertible into Common Stock on a 79.4784-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock effected by the Issuer on July 7, 2023) at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3. The Series E Preferred Stock has no expiration date.
F2 The shares underlying this option are fully vested and exercisable as of the date hereof.

Remarks:

Exhibit 24 - Power of Attorney